Investor Partners
Kleiner, Perkins, Caulfield and Buyers
Kleiner Perkins Caufield & Byers (KPCB) partners with the brightest entrepreneurs to turn disruptive ideas into world-changing businesses. The firm has helped build pioneering companies like Amazon, Electronic Arts, Genentech, Google, Nest, Netscape, and Twitter. KPCB offers entrepreneurs years of operating experience, puts them at the center of a vast and influential network, and accelerates their success through expertise and support in recruiting, product design and delivery, business development, strategic partnerships and brand building. KPCB invests in all stages from seed and incubation to growth companies and operates from offices in Menlo Park, San Francisco, Shanghai and Beijing.
http://www.kpcb.com/
TPG Biotech
TPG Biotech® is the life science venture investment arm of TPGSM (formerly known as Texas Pacific Group®), a global private investment firm. TPG Biotech® is a team of investors excited by the challenge of translating discoveries and insights in the biomedical sciences into tangible products. We invest with scientific founders and business entrepreneurs to create novel companies, and we focus on helping to drive the growth of our existing portfolio.
http://www.tpgbiotech.com/
Merck Serono Ventures
Merck Serono Ventures is a strategic, corporate venture capital fund that invests in emerging biotechnology companies. The fund invests in biotech start-up companies that have the potential to provide innovative products in Merck Serono’s core therapeutic areas, in particular in Neurodegenerative Diseases, Oncology, Autoimmune & Inflammatory Diseases, Endocrinology and Fertility. In addition, Merck Serono Ventures invests in companies developing innovative technologies that could enable the discovery and development of new products in Merck Serono’s core therapeutic areas.
http://www.emdserono.com
SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
We have a team of investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value.
Our current portfolio includes approximately 30 private and public companies and since our founding in 1985, we have invested over $680MM in the biotech space.
Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
http://www.srone.com/